Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Axol Bioscience, a leading pluripotent stem cell technology provider for drug discovery has signed an […]
Health Canada Accepts New Drug Submission for lecanemab as Treatment for Early Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that Health Canada has accepted a New Drug Submission […]
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]
Eli Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Eli Lilly and Company have announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study […]
Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced today positive interim results from the ongoing single ascending […]
Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease
Biomind Labs, a leading biotech company focused on developing the next generation of pharmaceuticals to […]
BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program
BIORCHESTRA, a biotherapeutics company focused on rare and degenerative diseases within the Central Nervous System […]
Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda
Treventis Corporation, a privately held biotechnology company, announced today that it has entered an option, […]
Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease
Roche announced today that it has entered into a collaboration with Eli Lilly and Company […]
TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment
TrueBinding, a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more